discussing mechanisms underlying Glutathione deficiency and validation of a novel nutritional intervention based on supplementing glycine and N-acetylcysteine (GlyNAC) to correct Glutathione deficiency in older-humans. Dr. Sekhar will present the results of a pilot 16-week pilot randomized, placebo-controlled, double-blind clinical trial in older humans investigating the effect of supplementing GlyNAC (vs. placebo) to improve Glutathione levels and oxidative-stress in 24 older-humans and 12 young-humans on impaired mitochondrial fuel-oxidation (MFO) and other defects. The trial met its primary objective that that GlyNAC supplementation (and not placebo) significantly improved Glutathione deficiency and corrected impaired MFO (and defects in its molecular regulation), and also significantly improved gaitspeed (increased 19% increase to match young-humans), muscle-strength, exercise-capacity, and lowered oxidativestress (80%) inflammation (IL-6 83%, TNF-alpha 58%), and insulin-resistance (68%). Dr. Taffet will discuss ageinduced diastolic heart failure, and the effect of supplementing GlyNAC (vs. NAC alone) in aged 24-month old mice with diastolic heart-failure, impaired myocardial MFO and cardiac-inflammation. Collectively this symposium on Glutathione and Aging will highlight the discovery that supplementing GlyNAC to correct Glutathione deficiency in older-humans has significant health benefits, and could be a novel nutritional-intervention in aging. The free-radical theory of aging suggests that age-related functional decline is mediated by increases in free-radical induced oxidative-stress. Cells normally depend on antioxidants for protection against oxidative-stress. Glutathione is the most abundant endogenous intracellular antioxidant protein composed of 3 amino-acids, cysteine, glycine and glutamic-acid, and is known to be deficient in older-humans. We investigated Glutathione kinetics in older humans using a stable-isotope tracer-based approach, and found that compared to younger humans, older-humans had severe Glutathione deficiency as a result of decreased synthesis caused by limited availability of glycine and cysteine, and associated with elevated oxidativestress. Orally supplementing glycine and cysteine (provided as N-acetylcysteine) at doses of 1.33mmol/kg/d and 0.81mmol/ kg/d respectively for 2-weeks corrected their intracellular deficiency, normalized Glutathione synthesis rates and lowered oxidative-stress to levels in younger controls. These results suggest that short-term supplementation of GlyNAC at these doses can successfully correct intracellular Glutathione deficiency in older-humans.
Aging is associated with impaired mitochondrial fattyacid oxidation (MFO) due to unknown mechanisms, and interventions are lacking. We hypothesized that impaired MFO in aging occurs due to Glutathione-deficiency and tested this in a randomized, placebo-controlled double-blind clinical-trial in 24 older-humans (71.1y) and 12 youngcontrols (25.5y) using calorimetry, muscle-biopsy and tracer-protocols. Older-humans received either GlyNAC (Glycine 1.33mmol/kg/d and N-acetylcysteine 0.83mmol/ kg/d as Glutathione precursors) or isonitrogenous-placebo for 16-weeks; young-controls received GlyNAC for 2-weeks. Compared to young-controls, older humans had significantly lower Glutathione, impaired MFO, lower gait-speed and physical-function, and higher oxidative-stress, inflammation and insulin-resistance. GlyNAC supplementation in olderhumans significantly improved and restored MFO; increased gait-speed (19%,) and physical-function; and decreased oxidative-stress (TBARS 80%), inflammation (IL-6 83%; TNF-alpha 58%), and insulin-resistance (HOMA-IR 68%), but young-controls were unaffected. These data provide proof-of-concept that GlyNAC supplementation could improve the health of older-humans by correcting Glutathionedeficiency and mitochondrial-defects to improve gait-speed, oxidative-stress, inflammation and insulin-resistance. Medicine, Houston, Texas, United States, 2. Houston Methodist Hospital, Houston, Texas, United States Impaired diastolic function is a risk factor for diastolic heart failure, may limit exercise performance, and is common in aging in both people and animals. This diastolic dysfunction seems to be associated with cardiac inflammation, fibrosis and impaired mitochondrial fatty acid metabolism. Old (24-28 m) mice fed a GlyNAC supplemented diet for 8 weeks were compared to those on control diet, and had dramatic improvement in all these parameters. For example, ATP generation from fatty acids with five-fold higher in the GlyNAC supplemented mice. In vitro studies compared NAC with GlyNAC and demonstrated the benefits only with supplementing both amino acids as compared to NAC alone. These data suggest that GlyNAC may have a role in improving cardiac function thus improving exercise tolerance and quality of life for older people.
GLUTATHIONE, INFLAMMATION, MITOCHONDRIAL FAT OXIDATION AND DIASTOLIC HEART FUNCTION IN OLD MICE

